Cancer Specialists of North Florida - Riverside
Jacksonville, FL
Accepting patients
Ruxolitinib
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- Kinase Inhibitor
- Phase 1
- Has results
Accepting patients
HLX15-SC
A Randomized, Double-blind, Parallel-controlled Phase I Study to Compare the Pharmacokinetic Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Monoclonal Antibody
- CD38
- Randomization
- Closed Label (Masked)
- Phase 1
Accepting patients
TRIlogy-3
A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
- Trispecific Antibody
- GPRC5D
- BCMA
- Phase 2